Patient survival and cardiovascular risk after kidney transplantation: The challenge of diabetes

被引:156
作者
Cosio, F. G. [1 ,4 ]
Hickson, L. J. [1 ,4 ]
Griffin, M. D. [1 ,4 ]
Stegall, M. D. [2 ,4 ]
Kudva, Y. [3 ,4 ]
机构
[1] Mayo Clin, Coll Med, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Surg, Rochester, MN USA
[3] Mayo Clin, Coll Med, Div Endocrinol, Rochester, MN USA
[4] Mayo Clin, Coll Med, Transplant Ctr, Rochester, MN USA
关键词
cardiovascular risk factors; diabetes mellitus; morbidity; mortality; survival;
D O I
10.1111/j.1600-6143.2007.02101.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
An increasing proportion of kidney recipients have diabetes mellitus (DM). Herein, we assessed the impact of DM on morbidity and mortality. The study included 933 recipients of first transplants. DM was present in 212 (23%). Compared to non-diabetics (NoDM), DM were older, heavier and had more pretransplant cardiovascular (CV) disease (16% vs. 48%, p < 0.0001). DM had reduced survival (5 years, 93% vs. 70%, p < 0.0001) and higher incidence of CV events (9% vs. 37%, p < 0.0001). CV disease was the most common cause of death in DM (61%) but not in NoDM (26%). Mortality from infections was also higher in DM (p = 0.001). In NoDM, survival related to recipient age (hazard ratio (HR) = 1.07, p < 0.0001) and dialysis pretransplant HR = 2.21, p = 0.01, while in DM, survival related to dialysis (HR = 2.89, p = 0.01) and pretransplant CV disease (HR = 2.79, p = 0.007). In NoDM, the incidence of posttransplant CV events was related to traditional CV risk factors, while in DM only the pretransplant CV history related to this outcome. In conclusion, survival differs between NoDM and DM recipients quantitatively, by cause of death and by risk factors. In NoDM, survival is excellent, and the main threat to survival relates to immunosuppression. In DM, survival is inferior primarily due to CV disease generally present prior to transplantation.
引用
收藏
页码:593 / 599
页数:7
相关论文
共 18 条
[1]   Preemptive transplantation for patients with diabetes-related kidney disease [J].
Becker, BN ;
Rush, SH ;
Dykstra, DM ;
Becker, YT ;
Port, FK .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (01) :44-48
[2]   Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies [J].
Cosio, Fernando G. ;
Amer, Hatem ;
Grande, Joseph P. ;
Larson, Timothy S. ;
Stegall, Mark D. ;
Griffin, Matthew D. .
TRANSPLANTATION, 2007, 83 (04) :411-416
[3]   Patient survival after renal transplantation: I. The impact of dialysis pre-transplant [J].
Cosio, FG ;
Alamir, A ;
Yim, S ;
Pesavento, TE ;
Falkenhain, ME ;
Henry, ML ;
Elkhammas, EA ;
Davies, EA ;
Bumgardner, GL ;
Ferguson, RM .
KIDNEY INTERNATIONAL, 1998, 53 (03) :767-772
[4]   New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation [J].
Cosio, FG ;
Kudva, Y ;
van der Velde, M ;
Larson, TS ;
Textor, SC ;
Griffin, MD ;
Stegall, MD .
KIDNEY INTERNATIONAL, 2005, 67 (06) :2415-2421
[5]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119
[6]   Effects of fluvastatin on cardiac events in renal transplant patients:: ALERT (Assessment of Lescol® in Renal Transplantation) study design and baseline data [J].
Holdaas, H ;
Fellström, B ;
Holme, I ;
Nyberg, G ;
Fauchald, P ;
Jardine, A ;
Grönhagen-Riska, C ;
Madser, S ;
Neumayer, HH ;
Cole, E ;
Maes, B ;
Weinreich, T ;
Olsson, AG ;
Pedersen, TR ;
Benghozi, R ;
Hartmann, A .
JOURNAL OF CARDIOVASCULAR RISK, 2001, 8 (02) :63-71
[7]   Cardiovascular risk and renal transplantation:: Post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) study [J].
Jardine, AG ;
Fellström, B ;
Logan, JO ;
Cole, E ;
Nyberg, G ;
Grönhagen-Riska, C ;
Madsen, S ;
Neumayer, HH ;
Maes, B ;
Ambühl, P ;
Olsson, AG ;
Pedersen, T ;
Holdaas, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (03) :529-536
[8]  
Kasiske BL, 2000, J AM SOC NEPHROL, V11, P1735, DOI 10.1681/ASN.V1191735
[9]   Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? [J].
Levey, AS ;
Beto, JA ;
Coronado, BE ;
Eknoyan, G ;
Foley, RN ;
Kasiske, BL ;
Klag, MJ ;
Mailloux, LU ;
Manske, CL ;
Meyer, KB ;
Parfrey, PS ;
Pfeffer, MA ;
Wenger, NK ;
Wilson, PWF ;
Wright, JT .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :853-906
[10]  
LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159